Listen to Gynecologic Oncology Gynecologic Oncology
-
- Science
Listen to the latest news from the experts in your field.
-
Editor's Choice: SENTIREC-endo study: Is the juice worth the squeeze?
Editor’s Choice Paper:
Identifying safe diagnostic algorithms for sentinel lymph node mapping in high-risk endometrial cancer: The SENTIREC-endo study
Editorial:
Sentinel lymph node biopsy in high-risk endometrial cancer: The dénouement
Hosted by:
Gregg Nelson, MD, Social Media Editor of Gynecologic Oncology
Featuring:
Sarah M. Bjørnholt, MD, Aarhus University Hospital, Denmark
Sean Dowdy, MD, Mayo Clinic, USA -
Editor's Choice: Caring for the Caregiver
Editor’s Choice Paper:
Experiences of patients with peritoneal carcinomatosis-related complex care needs and their caregivers
Editorial:
The importance of family-focused care in the setting of advanced gynecological cancers
Hosted by:
Sean Dowdy, MD, Associate Editor of Gynecologic Oncology
Featuring:
Rachel A. Pozzar, PhD, RN, Dana Farber Cancer Institute and Harvard Medical School
Allison J. Applebaum, PhD, Caregivers Clinic, Memorial Sloan Kettering Cancer Center -
Editor’s Choice: Lunchbox Trial
Editor’s Choice Paper:
Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma
Editorial:
What's in your “lunchbox”? Sandwich versus sequential chemotherapy and irradiation for advanced endometrial cancer
Hosted by:
Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology
Featuring:
Joyce Barlin, MD, Women’s Cancer Care Associates & Albany Medical College
Gretchen Glaser, MD, Mayo Clinic
John Weroha, MD, Mayo Clinic -
October 2023 Editor’s Choice: OS updates for Imagyn50
Editor’s Choice Paper:
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
Hosted by:
Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology
Featuring:
Kathleen N. Moore, MD, GOG-F and Stephenson Cancer Center at the University of Oklahoma Health Sciences Center -
September 2023 Editor’s Choice: Is now the time to begin thromboprophylaxis for all patients with advanced ovarian cancer, including those undergoing neoadjuvant chemotherapy?
Editor’s Choice Paper:
Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?
Editorial: Universal thromboprophylaxis in ovarian cancer patients before and after surgery?
Hosted by:
David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic Oncology
Featuring:
Amanika Kumar, MD, Mayo Clinic
Laura Havrilesky, MD, Duke University -
May 2023 Editor's Choice: Prioritizing and achieving diversity in clinical trial enrollment
Editor’s Choice Papers:
What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women
Editorial: Achieving diversity in clinical trial enrollment by reducing burden and increasing value: A patient-centered approach
Hosted by:
Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology
Featuring:
Ann Oluloro, MD, MPH, University of Washington
Eloise Chapman-Davis, MD, Weill Cornell Medicine